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Streszczenie
Osteoporoza jest ważnym problemem zdrowotnym 
dzisiejszych czasów. W większości przypadków dotyczy 
kobiet w okresie pomenopauzalnym. Rozwija się zwykle 
powoli i początkowo ma bezobjawowy przebieg. Często 
pierwszym jej objawem i groźnym powikłaniem jest 
złamanie kości. Skutki tego zdarzenia mogą wpływać 
negatywnie na jakość życia oraz mogą być przyczyną 
zwiększonej umieralności tej populacji. Efektywna 
prewencja i leczenie osteoporozy polega na identyfikacji 
i ocenie indywidualnego ryzyka złamania kości. Do tego 
celu można wykorzystać wiele metod diagnostycznych, 
w tym również metody genetyczne. Celem badania była 
ocena, które z różnych wariantów genotypu związane są 
z występowaniem choroby oraz mają wpływ na gęstość 
mineralną kości. Obserwacji poddano 261 pacjentek 
z osteoporozą pomenopauzalną. W badaniu ocenie 
poddano polimorfizmy następujących genów: OPG, 
VDR, ESR1, TGFB1, COL1A1 oraz BMP2.
Znamienność statystyczną pomiędzy wartościami 
gęstości mineralnej kości a polimorfizmem genu 
wykazano tylko dla allelu T TaqI genu VDR. W populacji 
kobiet z osteoporozą pomenopauzalną, zamieszkujących 
teren Wielkopolski, stwierdzono częstsze występowanie 
genotypu aa dla ApaI, bb dla Bsm i TT dla Taq genu VDR 
u pacjentek z większym ryzykiem złamania kości.
(Endokrynol Pol 2005; 2(56): 233-239)
Słowa kluczowe: osteoporoza, złamanie kości, 
polimorfizm
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Abstract
The major public health problem which will arise is 
a frequency of osteoporosis. The first manifestations 
of this disease are often bone fractures. Identification 
and evaluation of individual bone fracture risk will be 
the most effective way of solving the problem. Genetic 
determination of osteoporosis is unquestionable. 
The aim of this study is to detect which variants of 
genotypes lead to illness. We investigated 187 patients 
with osteoporosis (161 women, 26 men) and 19 healthy 
subjects. Polymorphisms of the following genes were 
investigated: OPG, VDR, ESR1, TGFB1 COL1A1, and 
BMP2. The statistically significant relationship between 
BMD value and T allele of Taq I VDR gene were found. 
Genotypes: aa, bb, TT of VDR gene occur more frequently 
in polish osteoporotic population in Wielkopolska region 
within patients with higher risk of bone fractures. 
(Pol J Endocrinol 2005; 3(56): 233-239)
Key words: osteoporosis, bone fractures, gene 
polymorphisms
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Abbreviations: 
OPG – Osteoprotegerin gene
VDR – Vitamin D receptor gene
ESR1- Estrogen receptor gene 1
TGFB1 - Transforming growth factor beta 1 gene
COL1A1 – Collagen type 1 alpha 1 gene
BMP2 – Bone morphogenetic protein 2 gene
BMD – bone mass density
Introduction
The frequency of osteoporosis is in proportion to 
increasing number of elderly people. Changes in 
bone structure cause skeleton distortions, bone 
aches, difficulties in everyday activity, and what 
is the most dangerous, bone fractures. The aim of 
osteoporosis treatment is to prevent such events. 
Demographic data indicate that the problem of 
osteoporosis will increase. Even now due to convin-
cing data osteoporosis is underdiagnosed and under-
rated [1]. Diagnosis of osteoporosis due to defini-
tion of IOF (International Osteoporotic Foundation) 
is based on Bone Mass Density (BMD) index. The 
estimation of risk of bone fractures due to low BMD 
index remains still not enough accurate. This occurs 
due to many different factors involved in origin of 
osteoporosis. These factors include: micro architec-
ture, the quality of matrix, bone flexibility and the 
pace of metabolic processes [2]. 
Achievements of molecular biology provide 
new prospectives in research on origins of many 
diseases. Genetic determinations of osteoporosis 
are unquestionable. Many studies on variability of 
candidate genes were performed. The subjects of 
these studies include genes which code proteins of 
bone metabolism. They are i.e.: vitamin D receptor 
(VDR), estrogen receptor (ESR1), calcitonin receptor 
(CALCR), parathyroid hormone receptor 1 (PTHR1), 
collagen type I alpha 1 (COL1A1), tumor necrosis 
factor (TNF), interleukin 6 (IL6), interleukin 1 
receptor antagonist (IL1RN), transforming growth 
factor beta 1 (TGFB1), low density lipoprotein 
receptor related protein 5 (LRP5) and osteoprote-
gerin (OPG) [3, 4, 5, 6, 7, 8, 9, 10, 11].
The question is simple: what variants of 
genotype lead to illness? Unfortunately the answer 
is complicated. There are differences in the results 
of studies. Interpretation of the results are difficult, 
because of few possible explanations: fenotypical 
manifestation of damaged genes depends not on 
one single gene, but on the group of them; influ-
ences of environment during life time can change 
genetic predisposition so much, that visible effects 
can be different. It is important to find in popula-
tion who are susceptible to osteoporosis. But even 
more important issue is to isolate in population of 
osteoporotic patients those with the highest risk of 
bone fractures. Such proceeding can change the 
form of treatment and allows setting individual 
therapy for single patient. This would be a great 
opportunity because every therapy is potentially 
harmful. Treatment of osteoporosis is long-lasting, 
provides side effects and is expensive.
The aim of this study was to estimate genetic 
predisposition to osteoporosis and/or fragility 
within postmenopausal women from Wielkopolska 
region of west Poland.
Material 
187 patients were included in the study (161 women 
and 26 men). Mean age of women 67.6, age from 45 
to 85, weight from 39 to 82, mean weight 60.2. Mean 
age of men 67.4, age from 47 to 84, weight from 57 
to 84, mean weight 72.4. 
In group with presence of fractures there were: 
56 patients with at least one osteoporotic bone 
fracture in history (51 women, age from 50 to 85 
mean age 69.7; weight from 49.5 to 82 kg mean 
weight 63.4 kg and 5 men, age from 48 to 76, mean 
age 58.2; weight from 63 to 84 kg, mean weight 74 
kg) and 131 patients with osteoporosis but without 
bone fractures in history (110 women, age from 
45 to 84, mean age 66.3; weight from 39 to 81 kg, 
mean weight 58.8 kg and 21 men, age from 53 to 
79, mean age 63.7; weight from 57 to 81 kg, mean 
weight 72 kg). 
187 patients were also divided in groups of 141 
patients with osteoporosis and 46 patients with 
osteopenia by BMD measurements as a basis of this 
division. 
The study was also performed in group of 19 
women (age from 52 to 77 years, mean age 63.2; 
mean weight 59.7) who come for their periodical 
examination with correct bone mass (mean T-score: 
-0.63 SD, measured in femoral neck). None of them 
had osteoporotic fractures or been pharmacologi-
cally treated. 
In all cases the polymorphisms of the following 
genes were examined: OPG, VDR, ESR1, TGFB1 
COL1A1, and BMP2. (Table 1)
Methods
DNA analysis. DNA was isolated from peripheral 
blood lymphocytes. PCR primers were designed 
using genomic GeneBank sequences of OPG, 
TGFB1 and BMP genes (OPGF-AAg gTg CAA AgT 
TTg gTC CAg g; OPGR-gTC TTC CAT AAA gTC 
AgC Agg; TGFB1F-TCC ggg CTg Cgg CTg CAg C; 
TGFB1R-gTT gTg ggT TTC CAC CAT TAg; BMP2F-
CCC CAC ggA ggA gTT TAT CAC; BMP2R-CCg 
ggg gAg CCA CAA TC). For VDR, ESR1, COL1A1 
genes the primers were designed according to litera-
ture data [11, 12]. 
The 20 µl reaction mixture contained 100 ng of 
genomic DNA, 50 mM KCl, 10 mM Tris-HCl (pH 
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8.3), 1.5 mM MgCl2, 0.25 mM dNTP, 30 ng of each 
primer and 0.6 unit of Taq DNA polymerase. The 
reaction was performed using cycling protocol of 
94°C for 40 s; annealing for 40 s (OPG-55°C; TGFB1-
57°C first 5 cycles and 54°C next 30 cycles; BMP2-
59°C); and 72°C for 100 s, for 35 cycles. In table 1 
analyzed polymorphisms and methods used for 
their genotyping are listed. Genotyping by SSCP 
was performed for 9G/C polymorphism of OPG 
gene. PCR products with 60% formamide were 
denatured and then resolved on native, 20×20 cm 
8% polyacrylamide gels (49:1 acrylamide:bisacry-
lamide) in 0.5×TBE buffer throughout 16h, 65V. 
Other polymorphisms were genotyped by RFLP. 
For polymorphism of Sp1 site in COL1A1 gene the 
primers were Cy5 labeled and fractionation was 
carried out on ALFexpress (Amersham-Pharmacia). 
Digestions with restriction enzymes were preformed 
following the manufacturer’s instructions. Polymor-
phisms and the method of genotyping are presented 
in Table 1. 
Table 1. Polymorphisms in analysis and the method 
of genotyping. (SSCP – single strand conformation 
polymorphism, RFLP – restriction fragment length 
polymorphism)
Gene Polymorphism The method of genotyping
OPG 9G/C SSCP
VDR
TaqI RFLP with restrictase TaqI
ApaI RFLP with restrictase Bsp120I
BsmI RFLP with restrictase Mva1269I
FokI RFLP with restrictase BseGI
ESR1
PvuII RFLP with restrictase PvuII
XbaI RFLP with restrictase XbaI
TGFB1 29T/C
RFLP with restrictase PvuII - 
restriction site was introduced 
by modified primer
COL1A1 Polymorphism of Sp1 site
RFLP with restrictase MlsI- 
restriction site was introduced 
by modified primer
BMP2 570T/A RFLP with restrictase BseNI
Results
The bone mineral densities (BMD) in femoral neck and 
in lumbar L2-L4 spine in patients with bone fractures 
and without them are presented on the Fig.1. 
The differences between T–score measure-
ments in groups of patients with and without bone 
fractures are not statistically significant. These data 
is presented in Table 2.
Table 2. The differences between mean T-scores in patients 
with bone fractures and without them measured in femoral 
neck and in lumbar spine L2-L4.
mean T-score Fractures no fractures difference
neck -2.51 -2.44 -0.07
spine -3.62 -2.93 -0.69
8
Fig.1. Bone mineral density measured in femoral neck [1] and in lumbar spine L2-L4 [2] in 
population of patients with bone fractures and without them.  
BMD in femoral neck [1] and in lumbar spine L2-L4 [2] in 
the study population. 
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The differences between T–score measurements in groups of patients with 
and without bone fractures are not statistically significant. These data is presented in 
Table 2. 
Table 2. The differences between mean T-scores in patients with bone fractures and without them 
measured in femoral neck and in lumbar spine L2-L4.
mean T-
score
Fractures
no
fractures 
difference 
neck -2.51 -2.44 -0.07 
spine -3.62 -2.93 -0.69 
Fig. 1. Bone mineral density measured in femoral neck [1] 
and in lumbar spine L2-L4 [2] in population of patients 
with bone fractures and without them.
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The frequency of osteoporotic fractures in compare with sex of patients is presented 
on .2 
Fig.2. The frequency of bone fractures in group women and men. 
Bone fractures in women and men.
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 The relation of bone fractures to whole group of osteoporotic 
patients is presented on Fig.3.   
Fig. 2. The frequency of bone fractures in group women 
and men.
10
Fig.3. Bone fractures in patients with osteoporosis ( Neck T-score < -2.5 SD). 
Bone fractures ratio.
34%
66%
fractures
 no fractures
There were investigated polymorphisms of genes: OPG, ESR1, VDR, TGFB1 
COL1A1, and BMP2 in patients with osteoporosis, osteopeny and in healthy 
subjects. Statistically significance results in T- allele Taq 1 VDR gene were found. 
These results are presented in the Table.3.  
Table.3. Dispositions of polymorphisms of investigated genes in patients with osteoporosis, 
osteopeny and in healthy subjects. (p<0.05) 
VDR Taq I Osteoporosis Osteopenia Healthy 
TT 64 19 2  
Tt 56 20 11  
tt 21 7 6 P 0.036 
Fig. 3. Bone fractures in patients with osteoporosis (Neck 
T-score < -2.5 SD).
The frequency of osteoporotic fractures in 
compare with sex of patients is presented on Fig. 2.
The re ation of bone fractur s to whole group of 
osteoporotic patients is presented on Fig. 3. 
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There were investigated polymorphisms of 
genes: OPG, ESR1, VDR, TGFB1 COL1A1, and 
BMP2 in patients with osteoporosis, osteopeny and 
in healthy subjects. Statistically significance results 
in T- allele Taq 1 VDR gene were found. These 
results are presented in the Table.3. 
Table 3. Dispositions of polymorphisms of investigated 
genes in patients with osteoporosis, osteopeny and in 
healthy subjects. (p<0.05)
VDR 
Taq I Osteoporosis Osteopenia Healthy
TT 64 19 2
Tt 56 20 11
tt 21 7 6 P 0.036
The groups of osteoporotic patients with bone 
fractures and without them were investigated to 
molecular variants of OPG, ESR1, VDR, TGFB1 
COL1A1, and BMP2 genes. 
Statistical methods. 
The Fisher-Freemann-Halton test for nonparametric 
data was used to evaluate the distribution of 
genotypes. The significance level was set at p<0.05. 
We have found statistically significant relationship 
between BMD and T-allele Taq I variant of VDR 
gene. The statistically significant differences were 
also found in polymorphism variants: a-allele Apa 
I, b-allele Bsm I and T-allele Taq I of vitamin D 
receptor gene in osteoporotic patients with bone 
fracture to compare to osteoporotic one without 
fracture. The results are shown on Fig. 4, 5 and 6.
Discussion 
The VDR gene is one of the most important 
candidate gene involved in osteoporosis develop-
ment, but not the only one. Finding genetic suscep-
tibility to osteoporosis is one of ways to identify 
individual predisposition to illness and can be a 
way to early protection. Environment factors can 
influence bone turnover mass in a few different 
ways. It is necessary to check populations in order 
to find any connections between genotype and 
an “osteoporotic fracture phenotype”. There are 
papers in which these kind correlations are detected 
[13, 14].
The important role of vitamin D3 in bone metabo-
lism regulations is proven by results of several 
studies investigating its influence on osteoporosis 
risk. There are reports confirming relation between 
genotype of VDR and bone mineral density [15, 16]. 
In study on polish population from Wielkopolska, 
we have found the predominance of T allele of the 
Taq I polymorphism of VDR gene in osteoporotic 
patients. This result is in accordance to ours earlier 
observations in polish population in pilot study 
[17]. Other data concerning European and Mexican 
11
The groups of osteoporotic patients with bone fractures and without them 
were investigated to molecular variants of OPG, ESR1, VDR, TGFB1 COL1A1, and
BMP2 genes.  
Statistical methods. The Fisher-Freemann-Halton test for nonparametric data was 
used to evaluate the distribution of genotypes. The significance level was set at 
p<0.05. We have found statistically significant relationship between BMD and T-
allele Taq I variant of VDR gene. The statistically significant differences were also 
found in polymorphism variants: a-allele Apa I, b-allele Bsm I and T-allele Taq I of 
vitamin D receptor gene in osteoporotic patients with bone fracture to compare to 
osteoporotic one without fracture. The results are shown on Fig. 4, 5 and 6. 
Fig.4. Genotypes T-allele, Tt, t-allele of Taq I polymorphism in VDR gene in osteoporotic patients 
with bone fractures (p=0.08)  
Disposition of polymorphism variant Taq I of vitamin D receptor 
gene in osteoporotic patients with bone fractures and without 
them.
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Fig.5. Genotypes B-allele, Bb, b-allele of Bsm I polymorphism in VDR gene in osteoporotic patients 
with bone fractures (p=0.06). 
Disposition of polymorphism variant Bsm I of vitamin D receptor 
gene in osteoporotic patients with bone fractures and without 
them.
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bb; 2618
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Fig.6. Genotypes A-allele, Aa, a-allele of polymorphism Apa I in VDR gene in osteoporotic patients 
with bone fractures (p=0.02).  
13
Disposition of polymorphism variant Apa I of vitamin 
D receptor gene in osteoporotic patients with bone 
fractures and without them. 
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Discussion
 The VDR gene is one of the most important candidate gene involved in 
osteoporosis development, but not the only one. Finding genetic susceptibility to 
osteoporosis is one of ways to identify individual predisposition to illness and can 
be a way to early protection. Environment factors can influence bone turnover mass 
in a few different ways. It is necessary to check populations in order to find any 
connections between genotype and an “osteoporotic fracture phenotype”. There are 
papers in which these kind correlations are detected [13, 14]. 
 The important role of vitamin D3 in bone metabolism regulations is proven 
by results of several studies investigating its influence on osteoporosis risk. There 
are reports confirming relation between genotype of VDR and bone mineral density 
[15, 16]. In study on polish population from Wielkopolska, we have found the 
predominance of T allele of the Taq I polymorphism of VDR gene in osteoporotic 
Fig. 4. Genotypes T-allele, Tt, t-allele of Taq I 
polymorphism in VDR gene in osteoporotic patients with 
bone fractures (p=0.08) 
Fig. 5. Genotypes B-allele, Bb, b-allele of Bsm I 
polymorphism in VDR gene in osteoporotic patients with 
bone fractures (p=0.06).
Fig. 6. Genotypes A-allele, Aa, a-allele of polymorphism 
Apa I in VDR gene in osteoporotic patients with bone 
fractures (p=0.02). 
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American population conclude similar results 
confirming relationship between VDR polymor-
phism and the risk of osteoporosis [18, 19]. There 
are also a reports in which relationship between 
polymorphism Taq1 VDR gene and bone density 
were not found [20] North American study which 
have not found any dependence between BMD 
and polymorphism of VDR gene. Possible expla-
nation of American results is that in their study 
Taq1 variant of VDR gene was not investigated 
[21]. The study in China also no confirm any signi-
ficant relationships between VDR gene and BMD 
index even they reported Taq1 polymorphism. The 
variance of results must be explained by presence of 
differences between populations or another possibi-
lities that environment factors can change so much 
genetic predisposition that the final phenotypes 
are so different [22, 23]. The consequence of gene 
mutations can be enhanced or inhibited because of 
activation of other genes and their products which 
play role in similar metabolic tracts [24]. That kind 
of activity can explain results of Morrison study in 
which relationship between VDR allel B and the 
risk of osteoporosis was found. In other studies 
the determination of low BMD is assigned to allel 
b VDR [19]. In our results although presence of b 
– allele of Bsm I of VDR gene was not exactly stati-
stically significant, but it was not far from that (p-
0.41), and it was frequent in patients with osteopo-
rosis 44% vs. 35% healthy and osteopenic subjects. 
It is possible that this result depends on changes in 
enzymatic activity of vitamin D3. Japanese authors 
also noticed correlation between dietary intake of 
vitamins and calcium and phenotype [28].Supple-
mentation of vitamin D3 in population living in 
area of high sun activity can be performed with 
less active vitamin D. But in population with low 
calcium diet the same metabolic activity of vitamin 
D3 is insufficient for proper calcium concentration 
[38]. In polish population level of vitamin D3 is very 
low in compare to other populations (French, Irish) 
[13]. 
In our study relationship between BMD and 
variants of other candidate genes such as: estrogen 
receptor (ESR1), osteoprotegerin (OPG), collagen 
type I ά 1, TGFβ1 and BMP1 have not been found. 
There are results of other studies confirming such 
correlation [26, 21, 27, 28]. There are also reports in 
agreement to our conclusion, in which that corre-
lation was not found [29, 28]. Again we suppose 
that, this is the result interpopulation differences in 
environment and genetic factors and their influence 
on determining bone metabolism.
The analysis of differences between variants 
of VDR gene in polish osteoporotic patients from 
Wielkopolska in Poland, with bone fractures 
resulted in finding the significant predominance of 
genotype a – allele of Apa 40% vs. 18%, b – allele of 
Bsm I 54% vs.39% and T-allele of TaqI 54% vs.41% 
VDR gene with p=0.02; 0.06; 0.08 respectively. The 
results of similar studies on population of United 
States confirmed the dependence between VDR 
genotype and risk of osteoporotic bone fractures 
[30, 31, 29]. Polymorphisms in exon 2, intron 8 and 
exon 9 of VDR gene were studied in Dutch popula-
tion. They found only that B – allele of the Bsm I in 
3 untranslated regions of the VDR was associated 
with low BMD in the hip and tended to be associated 
with fracture. On the other hand, any relationship 
between bone fractures and VDR polymorphism 
gene were not found in British, Spanish and Italy 
populations [32, 33 34, 35]. In Dutch population it 
was found again only that B – allele of Bsm I VDR 
is connected with predisposition to bone fracture. 
They also check other polymorphisms as: Fok I, 
Apa I and Taq I with negative results [31]. Results 
confirming correlations a-allele, b-allele and T-allele 
with BMD and higher risk of bone fracture come 
from Uitterlinden study performed in Nederland’s 
population [29]. 
Investigating populations’ predisposition to 
illness we detected many discrepancies between 
neighbor’s populations. It may be important to 
discover the reason why they exists. However polish 
population is located in central-eastern Europe we 
detected differences. 
Osteoporosis is a multifactor disease with 
undoubted genetic predisposition. It is possible like 
in other genetic illnesses which are visible in older 
age that the influences of many environment factors 
are even stronger that genetic predisposition to final 
phenotype. 
It is important to find who and why will be 
defected with osteoporosis. Strategy of investiga-
tion of gene polymorphism is based on knowledge 
of bone metabolic consequences of gene activity. 
The studies are often not successful because many 
past and present factors can change the final result. 
For example we have not found any correlation 
between bone fractures and BMD index in investi-
gated population in OPG gene with so strong 
influence on bone metabolism in theoretical point 
of view and studies confirming this correlation [13, 
29]. 
In polish population from Wielkopolska we also 
have not found statistically significant correlation 
between genotypes of genes ESR1, OPG, TGFB1, 
COL1A1, BMP2 and the risk of bone fractures. 
There are studies in which relationship between 
polymorphisms of these genes and bone fracture 
were found [38, 39]. Even there are also numerous 
studies reporting lack of such association [40, 41, 42, 
43]. It is possible that gene-gene relations (epistasis) 
can have so strong influence to final phenotype.
Nevertheless estimation of individual risk of 
bone fractures of patients with osteoporosis can be 
a proper way of setting a group of patients to whom 
a specific treatment should be applied. In whole 
P
R
A
C
E
  
O
R
Y
G
IN
A
L
N
E
238
P
R
A
C
E
  
O
R
Y
G
IN
A
L
N
E
Endokrynologia Polska / Polish Journal of Endocrinology  2005;  3 (56)
239
group of osteoporotic and osteopeny patients there 
were 56 cases (34%) with bone fractures. Using a 
sex of patient as an indicator we can predict a bone 
fracture in 5% of women and 10% of men. Although 
we found a difference between mean T-scores 
(measured in spine L2-L4) in patients with bone 
fractures (mean T-score -3.62) and without them 
(mean T-score -2.93). This difference (-0.69) is not 
significant and not can be useful in estimation of 
bone fracture risk. The difference (-0.07) in mean T-
scores (measured in femoral neck) in patients with 
bone fractures and without them was even lower 
and only slightly perceptible (Table.2.). Generally 
BMD value examination, as was published in many 
reports, does not allow prediction of bone fracture 
risk. Divide patients with similar value of BMD can 
not be done with satisfactory precision.
On this basis, we can assume, that molecular 
markers allow estimating bone fracture risk more 
precisely. The estimation of bone fracture risk 
probability using a method of molecular markers 
will be more precision comparing to the other. It is 
confirmed that among all genes polymorphisms the 
strongest relation to osteoporosis was detected in 
IL-6 gene and COL1A1 promotor gene region. But it 
is also unquestionably that interactions with dietary 
(very low intake of vitamin D3 in polish old women 
population) and lifestyle factors (exercise, smoking) 
can modulate bone metabolism and can be a reason 
of different results. Besides DNA mutations disco-
vered in promotor or exon regions influence protein 
synthesis. We can also expect that probably there 
will be difficulty to recognize by mutations in 
introns or especially in 3’ UTR untranslated region 
gene.
Conclusion 
1. In polish populations from Wielkopolska 
region relation between bone mass value and 
molecular variant Taq 1 o VDR gene was 
confirmed.
2. Patients with osteoporotic bone fractures in 
Wielkopolska region o Poland were more 
frequently a-allele of Apa 1, b-allele of Bsm 1 
and T-allele of Taq 1 VDR gene.
References
1.  Nguyen TV, Center JR, Eisman JA. (2004) Osteoporosis: 
underrated, underdiagnosed and undertreated. The Medical 
Journal of Australia; 180(5 Suppl): S18-22. 
2.  Badurski J, Czerwiński E, Gmiński J, Horst – Sikorska 
W, Marcinkowska – Suchowierska E, Milewicz A, Opala 
T, Tłustochowicz W. (2002) Stanowiska Rady Naukowej 
Polskiej Fundacji Osteoporozy wobec diagnostyki i leczenia 
Osteoporozy. Postępy Osteoartrologii; 13 (1-2): 9-10.
3.  Eisman J. (1999) Genetics of osteoporosis. Endocrine Reviews; 
20 (6): 788-804.
4.  Feng D. Ishibashi H, Yamamoto S, Hosoi T, Orimo H, 
Machida T, Koshihara Y. (2003) Association between bone 
loss and promoter polymorphism in the IL - 6 gene in elderly 
Japanese women with the hip fracture. Journal of Bone and 
Mineral Metabolism; 21 (4):225-8.
5.  Hering S, Isken E, Knabbe C, Janott J, Jost C, Pommer 
A, Muhr G, Schatz H, Pfeiffer AF. (2001) TGFbeta1 and 
TGFbeta2 mRNA and protein expression in human bone 
samples. Experimental Clinical Endocrinology Diabetes; 
109(4): 217-26.
6.  Huang QY, Shen H, Deng HY, Conway T, Davies KM, Li 
JL, Recker RP, Deng HW. (2003) Linkage and association 
of the CA repeat polymorphism of the IL 6 gene obesity 
– related phenotypes, and bone mineral density (BMD) in 
two independent Caucasian populations. Journal of Human 
Genetics. Jul 26 [Epub ahead by publisher].
7.  Mizuguchi T, Furuta I, Watanabe Y, Tsukamoto K, Ohta T. 
(2004) LRP5, low density – lipoprotein – receptor – related 
protein 5, is a determinant for bone mineral density. Journal 
of Human Genetics; 49(2): 80-6
8.  Ohmori H, Makita Y, Funamizu M, Hirooka K, Hosoi 
T, Orimo H, Suzuki T, Ikari K, Nakajima T, Inoue I, 
Hata A. (2002) Linkage and association analyses of the 
osteoprotegerin gene locus with human osteoporosis. Journal 
of Human Genetics; 47(8): 400-6.
9.  Sennels HP, Sand JC, Madsen B, Lauritzen JB, Fenger M, 
Jorgensen HL. (2003) Association between polymorphisms of 
apolipoprotein E, bone mineral density of the lower forearm, 
quantitative ultrasound of the calcaneus and osteoporotic 
fractures in postmenopausal women with hip or lower 
forearm fracture. The Scandinavian Journal of Clinical and 
Laboratory Investigations; 63(4):247-58.
10.  Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan FE, 
Grant SF, Hofman A, van Leeuwen JP, Pols HA, Ralston 
SH. (1998) Relation of alleles of the collagen type I alpha1 
gene to bone density and the risk of osteoporotic fractures 
in postmenopausal women. The New England Journal of 
Medicine. Apr 9; 338(15):1016-21.
11.  Grant, S. F. A., Reid, D. M., Blake, G., Herd, R., Fogelman, I., 
Ralston, S. H. (1996) Reduced bone density and osteoporosis 
associated with a polymorphic Sp1 binding site in the 
collagen type I alpha 1 gene. Nature Genetics; 14: 203-205.
12. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo 
H. (1996) Association of bone mineral density with 
polymorphism of the estrogen receptor gene. Journal of Bone 
and Mineral Research; 11: 306-311.
13. Andersen R, Brot C, Cashman KD, Habros E, Charzewska 
J. (2004) Hypovitaminosis D in Europe. Osteoporosis 
International; 15(Suppl 1):S7-8 
14. Kurabayashi T, Matsushita H, Kato N, Nagata H. (2004) 
Effect of vitamin D receptor and estrogen receptor gene 
polymorphism on the relationship between dietary calcium 
and bone mineral density in Japanese women. Journal of 
Bone and Mineral Metabolism; 22(2):139-147
15. Gong G, Haynatzki G. (2003) Association between 
bone mineral density and candidate genes in different 
ethnic populations and its implications. Calcified Tissue 
International; 72(2): 113-23.
16. Uitterlinden AG, Pols HA, Burger H, Huang Q, Van Daele 
PL, Van Duijn CM, Hofman A, Birkenhager JC, Van Leeuwen 
JP. (1996) A large-scale population-based study of the 
association of vitamin D receptor gene polymorphisms with 
bone mineral density. Journal of Bone and Mineral Research; 
11(9):1241-8.
17. Ziemnicka K, Horst–Sikorska W, Baszko–Błaszyk D, 
Kalak R, Kwiatkowska J, Słomski R. (2002) Polimorfizm 
genów receptora witaminy D3 I estrogenowego – badania 
w populacji kobiet z regionu Wielkopolski. Postępy 
Osteoartrologii; 13(1-2): 11-14
18. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, 
Feldman D. (1996) The presence of a polymorphism at the 
translation initiation site of the vitamin D receptor gene is 
associated with low bone mineral density in postmenopausal 
Mexican-American women. Journal of Bone and Mineral 
Research; 11(12):1850-5.
19. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, 
Polimorfizm VDR markerem złamań w osteoporozie pomenoapuzalnej Horst-Sikorska W.
P
R
A
C
E
  
O
R
Y
G
IN
A
L
N
E
238
P
R
A
C
E
  
O
R
Y
G
IN
A
L
N
E
Endokrynologia Polska / Polish Journal of Endocrinology  2005;  3 (56)
239
Nguyen TV, Sambrook PN, Eisman JA. (1994) Prediction 
of bone density from vitamin D receptor alleles.
Nature; 367(6460):284-7. Erratum in: Nature 1997 May 
1;387(6628):106. 
20. Zajickova K, Zofkova I. (2002) Vitamin D receptor gene 
polymorphisms, bone mineral density and bone turnover: 
FokI genotype is related to postmenopausal bone mass. 
Physiology Research; 51(5): 501-9. 
21. Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten 
C, Crutchfield M, D’Agostino D, Jannausch M. (1998) Bone 
mineral density and its change in white women: estrogen 
and vitamin D receptor genotypes and their interaction. 
Journal of Bone and Mineral Research; 13(4): 695-705. 
22. Dvornyk V., Liu X.H., Shen H., Lei S.F., Zhao L.J., Huang 
Q.R., Qin Y.J., Jiang D.K., Long J.R., Zhang Y.Y., Gong G., 
Recker R.R., Deng H.W. (2003) Differentiation of Caucasians 
and Chinese at bone mass candidate genes: implication for 
ethnic difference of bone mass. Annual Human Genetics; 
67(Pt 3): 216-27.
23.  Lei SF, Deng FY, Liu XH, Huang QR, Qin Y, Zhou Q, 
Jiang DK, Li YM, Mo XY, Liu MY, Chen XD, Wu XS, Shen 
H, Dvornyk V, Zhao L, Recker RR, Deng HW. (2003) 
Polymorphisms of four bone mineral density candidate 
genes in Chinese populations and comparison with other 
populations of different ethnicity. Journal of Bone and 
Mineral Metabolism; 21(1):34-42.
24. Huang QY, Recker RP, Deng HW. (2003) Searching for 
osteoporosis genes in the post – genome era: progress and 
challenges. Osteoporosis International. Aug 5 [E-pub ahead 
of print]
25. Francis RM, Harrington F, Tuner E, Papiha SS, Datta HK. 
(1997) Vitamin D receptor gene polymorphism in men 
and its effect on bone density and calcium absorption.
Clinical Endocrinology (Oxf); 46(1):83-6.
26. Ralston SH. (2003) Genetic determinants of susceptibility to 
osteoporosis. Current Opinion in Pharmacology; 3 (3): 286-
90.
27.  Yamada Y, Ando F, Niino N, Shimokata H. (2003) Association 
of polymorphism of interleukin – 6, osteocalcin, and vitamin 
receptor genes, alone or in combination, with bone mineral 
density in community – dwelling Japanese women and men. 
Journal of Clinical Endocrinology & Metabolism; 88 (7):3372-
8.
28. Zajickova K., Zofkova I. (2003) Osteoporosis: genetic analysis 
of multifactorial disease. Endocrine Regulations; 37(1): 31-
44. 
29.  Uitterlinden AG, Weel AE, Burger H, Fang Y, van Duijn CM, 
Hofman A, van Leeuwen JP, Pols HA. (2001) Interaction 
between the vitamin D receptor gene and collagen type 
Ialpha1 gene in susceptibility for fracture. Journal of Bone 
and Mineral Research; 16(2):379-85.
30. Feskanich D, Hunter DJ, Willett WC, Hankinson SE, Hollis 
BW, Hough HL, Kelsey KT, Colditz GA. (1998) Vitamin D 
receptor genotype and the risk of bone fractures in women. 
Epidemiology; 9(5):535-9.
31. Langdahl B., Gravholt C., Brixen K., Eriksen EF. (2000) 
Polymorphism in the vitamin D receptor gene and bone 
mass, bone turnover and osteoporotic fractures. European 
Journal of Clinical Investigation; 30, 608-17.
32. Alvarez-Hernandez D, Navez M, Diaz-Lopez JB, Gomez C. 
(2003) Influence of polymorphisms in VDR and COL1A1 
genes on the risk of osteoporotic fractures in aged men. 
Kidney International Suppl; (85): S14-8
33.  Braga V, Sangalli A, Malerba G, Mottes M. (2002) 
Relationship among VDR (BsmI and Fok I), COL1A1 and CTR 
polymorphisms with bone mass, bone turnover markers, and 
sex hormones in men. Calcified Tissue International; 70(6):
457-62 
34. Houston L, Grant S, Reid D, Ralston S. (1996) Vitamin 
D receptor polymorphism bone mineral density and 
osteoporotic vertebral fracture study in UK population. 
Bone; 18,249-252.
35.  Zarrabeitia MT, Riancho JA, Franco-Vicario R, Gorria J. (2000) 
Multiple genetic typing (vitamin D receptors and estrogens) 
in the assessments of the risk of fractures. Med Clin (Barc); 
114(7): 241-4
36. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, 
Bonelli C, Dimai HP, Leb G, Obermayer-Pietsch B. (2003) 
Osteoprotegerin serum levels in women: correlation with 
age, bone mass, bone turnover and fracture status. Wiener 
Klinische Wochenschrift; 115(9): 291-7.
37. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. (2002) 
Polymorphisms in the Osteoprotegerin gene are associated 
with osteoporotic fractures. Journal of Bone and Mineral 
Research; 17(7): 1245-55.
38.  Gerdhem P, Braandstroom H, Stiger F, Obrant K, Melhus H, 
Kindmark A, Akesson K. (2004) Association of the collagen 
type 1 (COL1A 1) Sp1 binding site polymorphism to femoral 
neck bone mineral density and wrist fracture in 1044 elderly 
Swedish women. Calcified Tissue International; 74(3): 264-9.
39.  van Meurs JB, Schuit SC, Weel AE, van der Klift M, Bergink 
AP, Arp PP, Colin EM, Fang Y, Hofman A, van Duijn CM, van 
Leeuwen JP, Pols HA, Uitterlinden AG. (2003) Association 
of 5’ estrogen receptor alpha gene polymorphisms with 
bone density, vertebral bone area and fracture risk. Human 
Molecular Genetics; 12(14): 1745-54.
40.  Aerssens J, Dequeker J, Peeters J, Breemans S, Broos P, 
Boonen S. (2000) Polymorphisms of the VDR, ER and 
COLIA1 genes and osteoporotic hip fractures in elderly 
postmenopausal women. Osteoporosis International; 11(7): 
583-91.
41.  Allcroft LC, Varanasi SS, Dimopoulos D, Francis RM, Datta 
HK. (2002) Mutational and polymorphic analysis of the 
estradiol receptor-alpha gene with symptomatic vertebral 
fractures. Calcified Tissue International; 71(5): 400-5.
42. Ioannidis JP, Stavrou I, Trikalinos TA, Zois C, Brandi ML, 
Gennari L, Albagha O, Ralston SH, Tsatsoulis A. (2002) 
Association of polymorphisms of the estrogen receptor alpha 
gene with bone mineral density and fracture risk in women: 
a meta-analysis. Journal of Bone and Mineral Research; 
17(11): 2048-60.
43.  Pluijm SM, van Essen HW, Bravenboer N, Uitterlinden AG, 
Smit JH, Pols HA, Lips P. (2003) Collagen type I alpha1 Sp1 
polymorphism, osteoporosis and intervertebral degeneration 
in older men and women. Annals of the Rheumatic Diseases; 
63(1):71-7.
